(-)-epigallocatechin 3-gallate multiple interactions ISO RGD:1314209 6480464 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KAT2B mRNA CTD PMID:22079256 (1->4)-beta-D-glucan multiple interactions ISO RGD:1314210 6480464 [perfluorooctane sulfonic acid co-treated with Cellulose] results in decreased expression of KAT2B mRNA CTD PMID:36331819 (S)-naringenin increases expression ISO RGD:1314209 6480464 naringenin metabolite results in increased expression of KAT2B mRNA CTD PMID:36235125 (S)-naringenin multiple interactions ISO RGD:1314209 6480464 [naringenin co-treated with bisphenol A] results in increased expression of KAT2B mRNA, [naringenin metabolite co-treated with bisphenol A] results in increased expression of KAT2B mRNA CTD PMID:36235125 1,2-dichloroethane decreases expression ISO RGD:1314210 6480464 ethylene dichloride results in decreased expression of KAT2B mRNA CTD PMID:28189721 , PMID:28960355 1,2-dimethylhydrazine decreases expression ISO RGD:1314210 6480464 1, 2-Dimethylhydrazine results in decreased expression of KAT2B mRNA CTD PMID:22206623 17alpha-ethynylestradiol affects expression ISO RGD:1314209 6480464 Ethinyl Estradiol affects the expression of KAT2B mRNA CTD PMID:20170705 , PMID:26865667 17alpha-ethynylestradiol decreases expression ISO RGD:1314209 6480464 Ethinyl Estradiol results in decreased expression of KAT2B mRNA CTD PMID:18936297 17alpha-ethynylestradiol affects expression EXP 6480464 Ethinyl Estradiol affects the expression of KAT2B mRNA CTD PMID:20170705 , PMID:26865667 17beta-estradiol decreases expression ISO RGD:1314210 6480464 Estradiol results in decreased expression of KAT2B mRNA CTD PMID:25210133 17beta-estradiol increases expression ISO RGD:1314209 6480464 Estradiol results in increased expression of KAT2B mRNA CTD PMID:19619570 17beta-estradiol multiple interactions ISO RGD:1314209 6480464 [Estradiol co-treated with Tetrachlorodibenzodioxin] results in increased expression of KAT2B mRNA more ... CTD PMID:19619570 more ... 17beta-hydroxy-17-methylestra-4,9,11-trien-3-one multiple interactions ISO RGD:1314209 6480464 [Metribolone binds to and affects the folding of AR protein] inhibits the reaction [AR protein modified form binds to KAT2B protein modified form] CTD PMID:28751236 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO RGD:1314210 6480464 Tetrachlorodibenzodioxin affects the expression of KAT2B mRNA CTD PMID:21570461 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO RGD:1314210 6480464 Tetrachlorodibenzodioxin results in decreased expression of KAT2B mRNA CTD PMID:33956508 2,3,7,8-tetrachlorodibenzodioxine multiple interactions ISO RGD:1314209 6480464 [Estradiol co-treated with Tetrachlorodibenzodioxin] results in increased expression of KAT2B mRNA CTD PMID:19619570 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:1314209 6480464 Tetrachlorodibenzodioxin results in increased expression of KAT2B mRNA CTD PMID:19619570 more ... 2,4-dinitrotoluene affects expression EXP 6480464 2, 4-dinitrotoluene affects the expression of KAT2B mRNA CTD PMID:21346803 2-Hydroxy-6-(8,11,14-pentadecatrienyl)benzoic acid decreases activity ISO RGD:1314210 6480464 anacardic acid results in decreased activity of KAT2B protein CTD PMID:31927229 3,5-diethoxycarbonyl-1,4-dihydrocollidine decreases expression ISO RGD:1314210 6480464 Dicarbethoxydihydrocollidine results in decreased expression of KAT2B mRNA CTD PMID:18098314 4-hydroxyphenyl retinamide decreases expression ISO RGD:1314210 6480464 Fenretinide results in decreased expression of KAT2B mRNA CTD PMID:28973697 5-aza-2'-deoxycytidine multiple interactions ISO RGD:1314209 6480464 Decitabine promotes the reaction [KAT2B protein binds to TP53 protein] CTD PMID:17977830 acetyl-CoA affects binding ISO RGD:1314210 6480464 Acetyl Coenzyme A binds to KAT2B protein CTD PMID:28077572 acrylamide decreases expression EXP 6480464 Acrylamide results in decreased expression of KAT2B mRNA CTD PMID:28959563 aflatoxin B1 increases methylation ISO RGD:1314209 6480464 Aflatoxin B1 results in increased methylation of KAT2B intron CTD PMID:30157460 Aflatoxin B2 alpha increases methylation ISO RGD:1314209 6480464 aflatoxin B2 results in increased methylation of KAT2B intron CTD PMID:30157460 aflatoxin M1 decreases expression ISO RGD:1314209 6480464 Aflatoxin M1 results in decreased expression of KAT2B mRNA CTD PMID:30928695 all-trans-retinoic acid multiple interactions ISO RGD:1314210 6480464 Tretinoin affects the reaction [KAT2B protein binds to NR2C1 promoter] CTD PMID:17389641 all-trans-retinoic acid increases expression ISO RGD:1314209 6480464 Tretinoin results in increased expression of KAT2B mRNA, Tretinoin results in increased expression of KAT2B protein CTD PMID:28053092 all-trans-retinoic acid multiple interactions ISO RGD:1314209 6480464 KAT2B protein promotes the reaction [Tretinoin results in increased expression of CCL2 mRNA] more ... CTD PMID:16050810 , PMID:28053092 ammonium chloride increases expression EXP 6480464 Ammonium Chloride results in increased expression of KAT2B protein CTD PMID:16483693 arsenite(3-) multiple interactions ISO RGD:1314209 6480464 arsenite inhibits the reaction [G3BP1 protein binds to KAT2B mRNA] CTD PMID:32406909 arsenous acid increases expression ISO RGD:1314209 6480464 Arsenic Trioxide results in increased expression of KAT2B mRNA CTD PMID:20458559 atrazine decreases expression ISO RGD:1314209 6480464 Atrazine results in decreased expression of KAT2B mRNA CTD PMID:22378314 benzo[a]pyrene decreases expression ISO RGD:1314209 6480464 Benzo(a)pyrene results in decreased expression of KAT2B mRNA CTD PMID:21714911 , PMID:32234424 benzo[a]pyrene increases expression ISO RGD:1314209 6480464 Benzo(a)pyrene results in increased expression of KAT2B mRNA CTD PMID:30453624 benzo[a]pyrene decreases expression ISO RGD:1314210 6480464 Benzo(a)pyrene results in decreased expression of KAT2B mRNA CTD PMID:22228805 benzo[e]pyrene increases methylation ISO RGD:1314209 6480464 benzo(e)pyrene results in increased methylation of KAT2B intron CTD PMID:30157460 Benzo[k]fluoranthene decreases expression ISO RGD:1314210 6480464 benzo(k)fluoranthene results in decreased expression of KAT2B mRNA CTD PMID:26377693 bis(2-chloroethyl) sulfide decreases expression ISO RGD:1314210 6480464 Mustard Gas results in decreased expression of KAT2B mRNA CTD PMID:26392148 bisphenol A multiple interactions ISO RGD:1314210 6480464 [potassium bromate co-treated with bisphenol A] affects the expression of KAT2B mRNA, [XRCC6 gene mutant form results in increased susceptibility to potassium bromate] affects the reaction [[potassium bromate co-treated with bisphenol A] affects the expression of KAT2B mRNA] CTD PMID:27082013 bisphenol A multiple interactions ISO RGD:1314209 6480464 [naringenin co-treated with bisphenol A] results in increased expression of KAT2B mRNA, [naringenin metabolite co-treated with bisphenol A] results in increased expression of KAT2B mRNA CTD PMID:36235125 bisphenol A increases expression ISO RGD:1314210 6480464 bisphenol A results in increased expression of KAT2B mRNA CTD PMID:30303745 bisphenol A decreases expression EXP 6480464 bisphenol A results in decreased expression of KAT2B mRNA CTD PMID:25181051 bisphenol A affects expression ISO RGD:1314209 6480464 bisphenol A affects the expression of KAT2B mRNA CTD PMID:20170705 bortezomib decreases expression ISO RGD:1314209 6480464 Bortezomib results in decreased expression of KAT2B mRNA CTD PMID:20471514 buta-1,3-diene increases expression ISO RGD:1314210 6480464 1, 3-butadiene results in increased expression of KAT2B mRNA CTD PMID:25237060 butanal decreases expression ISO RGD:1314209 6480464 butyraldehyde results in decreased expression of KAT2B mRNA CTD PMID:26079696 butyryl-CoA affects binding ISO RGD:1314210 6480464 butyryl-coenzyme A binds to KAT2B protein CTD PMID:28077572 cadmium atom decreases expression ISO RGD:1314209 6480464 Cadmium results in decreased expression of KAT2B mRNA CTD PMID:24376830 carbon nanotube increases expression ISO RGD:1314210 6480464 Nanotubes, Carbon results in increased expression of KAT2B mRNA CTD PMID:25554681 CGP 52608 multiple interactions ISO RGD:1314209 6480464 CGP 52608 promotes the reaction [RORA protein binds to KAT2B gene] CTD PMID:28238834 chromium(6+) decreases expression ISO RGD:1314209 6480464 chromium hexavalent ion results in decreased expression of KAT2B mRNA CTD PMID:30690063 cisplatin increases expression ISO RGD:1314210 6480464 Cisplatin results in increased expression of KAT2B mRNA CTD PMID:21151649 cisplatin multiple interactions ISO RGD:1314209 6480464 [Cisplatin co-treated with jinfukang] results in decreased expression of KAT2B mRNA CTD PMID:27392435 coenzyme A affects binding ISO RGD:1314210 6480464 Coenzyme A binds to KAT2B protein CTD PMID:28077572 coumestrol multiple interactions ISO RGD:1314209 6480464 [Coumestrol co-treated with resveratrol] results in decreased expression of KAT2B mRNA CTD PMID:19167446 coumestrol decreases expression ISO RGD:1314209 6480464 Coumestrol results in decreased expression of KAT2B mRNA CTD PMID:19167446 Cuprizon decreases expression EXP 6480464 Cuprizone results in decreased expression of KAT2B mRNA CTD PMID:27523638 cyclosporin A decreases expression ISO RGD:1314209 6480464 Cyclosporine results in decreased expression of KAT2B mRNA CTD PMID:20106945 , PMID:25562108 cyclosporin A decreases methylation ISO RGD:1314209 6480464 Cyclosporine results in decreased methylation of KAT2B promoter CTD PMID:27989131 deoxynivalenol multiple interactions ISO RGD:1314209 6480464 KAT2B protein affects the reaction [deoxynivalenol results in increased expression of ATF3 protein alternative form] CTD PMID:30286430 deoxynivalenol increases expression ISO RGD:1314209 6480464 deoxynivalenol results in increased expression of KAT2B protein CTD PMID:30286430 dexamethasone increases expression ISO RGD:1314209 6480464 Dexamethasone results in increased expression of KAT2B mRNA CTD PMID:19022236 diarsenic trioxide increases expression ISO RGD:1314209 6480464 Arsenic Trioxide results in increased expression of KAT2B mRNA CTD PMID:20458559 dibutyl phthalate increases expression ISO RGD:1314210 6480464 Dibutyl Phthalate results in increased expression of KAT2B mRNA CTD PMID:21266533 disodium selenite decreases expression ISO RGD:1314209 6480464 Sodium Selenite results in decreased expression of KAT2B mRNA CTD PMID:18175754 dorsomorphin multiple interactions ISO RGD:1314209 6480464 [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... CTD PMID:27188386 doxorubicin increases expression ISO RGD:1314209 6480464 Doxorubicin results in increased expression of KAT2B mRNA CTD PMID:16001973 doxorubicin decreases expression ISO RGD:1314209 6480464 Doxorubicin results in decreased expression of KAT2B mRNA CTD PMID:29803840 entinostat multiple interactions ISO RGD:1314209 6480464 [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT2B mRNA CTD PMID:27188386 entinostat decreases expression ISO RGD:1314209 6480464 entinostat results in decreased expression of KAT2B mRNA CTD PMID:26272509 enzalutamide affects expression ISO RGD:1314209 6480464 enzalutamide affects the expression of KAT2B mRNA CTD PMID:30940724 ethyl methanesulfonate increases expression ISO RGD:1314209 6480464 Ethyl Methanesulfonate results in increased expression of KAT2B mRNA CTD PMID:23649840 fluvastatin multiple interactions ISO RGD:1314209 6480464 [zoledronic acid co-treated with fluvastatin] results in increased expression of KAT2B mRNA CTD PMID:16996129 formaldehyde increases expression ISO RGD:1314209 6480464 Formaldehyde results in increased expression of KAT2B mRNA CTD PMID:23649840 genistein decreases expression ISO RGD:1314209 6480464 Genistein results in decreased expression of KAT2B mRNA CTD PMID:26865667 gentamycin decreases expression EXP 6480464 Gentamicins results in decreased expression of KAT2B mRNA CTD PMID:22061828 glafenine decreases expression EXP 6480464 Glafenine results in decreased expression of KAT2B mRNA CTD PMID:24136188 hydroxyurea increases expression ISO RGD:1314210 6480464 Hydroxyurea results in increased expression of KAT2B mRNA CTD PMID:27208086 irinotecan increases expression ISO RGD:1314209 6480464 Irinotecan analog results in increased expression of KAT2B mRNA CTD PMID:18927307 isobutyryl-CoA affects binding ISO RGD:1314210 6480464 isobutyryl-coenzyme A binds to KAT2B protein CTD PMID:28077572 linalool multiple interactions ISO RGD:1314209 6480464 linalool inhibits the reaction [KAT2B protein binds to HMGCR promoter] CTD PMID:21944868 methapyrilene increases methylation ISO RGD:1314209 6480464 Methapyrilene results in increased methylation of KAT2B intron CTD PMID:30157460 methapyrilene decreases expression EXP 6480464 Methapyrilene results in decreased expression of KAT2B mRNA CTD PMID:30467583 methidathion increases expression ISO RGD:1314210 6480464 methidathion results in increased expression of KAT2B mRNA CTD PMID:34813904 methotrexate increases expression ISO RGD:1314209 6480464 Methotrexate results in increased expression of KAT2B mRNA CTD PMID:21678067 methotrexate multiple interactions ISO RGD:1314209 6480464 Methotrexate promotes the reaction [E2F1 protein binds to KAT2B protein] CTD PMID:22484375 methyl methanesulfonate increases expression ISO RGD:1314209 6480464 Methyl Methanesulfonate results in increased expression of KAT2B mRNA CTD PMID:23649840 methylmercury chloride decreases expression ISO RGD:1314209 6480464 methylmercuric chloride results in decreased expression of KAT2B mRNA CTD PMID:28001369 methylparaben decreases expression ISO RGD:1314209 6480464 methylparaben results in decreased expression of KAT2B mRNA CTD PMID:31745603 N-nitrosodiethylamine decreases expression EXP 6480464 Diethylnitrosamine results in decreased expression of KAT2B mRNA CTD PMID:19638242 nickel dichloride affects expression EXP 6480464 nickel chloride affects the expression of KAT2B mRNA CTD PMID:22546817 ozone multiple interactions ISO RGD:1314210 6480464 [Air Pollutants results in increased abundance of Ozone] which results in decreased expression of KAT2B mRNA CTD PMID:27106289 panobinostat multiple interactions ISO RGD:1314209 6480464 [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT2B mRNA CTD PMID:27188386 panobinostat decreases expression ISO RGD:1314209 6480464 panobinostat results in decreased expression of KAT2B mRNA CTD PMID:26272509 paracetamol increases expression ISO RGD:1314209 6480464 Acetaminophen results in increased expression of KAT2B mRNA CTD PMID:22230336 paracetamol affects expression ISO RGD:1314210 6480464 Acetaminophen affects the expression of KAT2B mRNA CTD PMID:17562736 perfluorooctane-1-sulfonic acid decreases expression ISO RGD:1314209 6480464 perfluorooctane sulfonic acid results in decreased expression of KAT2B mRNA CTD PMID:27153767 perfluorooctane-1-sulfonic acid multiple interactions ISO RGD:1314210 6480464 [perfluorooctane sulfonic acid co-treated with Cellulose] results in decreased expression of KAT2B mRNA CTD PMID:36331819 phenobarbital affects expression ISO RGD:1314210 6480464 Phenobarbital affects the expression of KAT2B mRNA CTD PMID:23091169 phenobarbital decreases expression ISO RGD:1314210 6480464 Phenobarbital results in decreased expression of KAT2B mRNA CTD PMID:19363144 phenylmercury acetate decreases expression ISO RGD:1314209 6480464 Phenylmercuric Acetate results in decreased expression of KAT2B mRNA CTD PMID:26272509 phenylmercury acetate multiple interactions ISO RGD:1314209 6480464 [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT2B mRNA CTD PMID:27188386 potassium bromate multiple interactions ISO RGD:1314210 6480464 [potassium bromate co-treated with bisphenol A] affects the expression of KAT2B mRNA, [XRCC6 gene mutant form results in increased susceptibility to potassium bromate] affects the reaction [[potassium bromate co-treated with bisphenol A] affects the expression of KAT2B mRNA] CTD PMID:27082013 potassium chromate decreases expression ISO RGD:1314209 6480464 potassium chromate(VI) results in decreased expression of KAT2B mRNA CTD PMID:22079256 , PMID:22714537 potassium chromate multiple interactions ISO RGD:1314209 6480464 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of KAT2B mRNA CTD PMID:22079256 propiconazole decreases expression ISO RGD:1314210 6480464 propiconazole results in decreased expression of KAT2B mRNA CTD PMID:19363144 , PMID:21278054 prostaglandin E2 multiple interactions ISO RGD:1314209 6480464 KAT2B protein affects the reaction [Dinoprostone promotes the reaction [EP300 protein binds to CYP19A1 promoter]] more ... CTD PMID:30409902 quercetin increases expression ISO RGD:1314209 6480464 Quercetin results in increased expression of KAT2B mRNA CTD PMID:21632981 resveratrol multiple interactions ISO RGD:1314209 6480464 [Coumestrol co-treated with resveratrol] results in decreased expression of KAT2B mRNA, resveratrol affects the reaction [TNF protein promotes the reaction [KAT2B protein binds to IL6 promoter]] CTD PMID:19167446 , PMID:24771768 resveratrol increases expression ISO RGD:1314209 6480464 resveratrol results in increased expression of KAT2B mRNA CTD PMID:15767336 SB 431542 multiple interactions ISO RGD:1314209 6480464 [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... CTD PMID:27188386 sodium arsenate decreases expression ISO RGD:1314210 6480464 sodium arsenate results in decreased expression of KAT2B protein CTD PMID:26193056 sodium arsenite decreases expression ISO RGD:1314210 6480464 sodium arsenite results in decreased expression of KAT2B mRNA CTD PMID:19822182 sodium arsenite decreases expression ISO RGD:1314209 6480464 sodium arsenite results in decreased expression of KAT2B mRNA CTD PMID:32844245 sodium fluoride multiple interactions ISO RGD:1314210 6480464 Sodium Fluoride promotes the reaction [TRP53 protein binds to KAT2B protein] CTD PMID:31927229 sulforaphane increases expression ISO RGD:1314209 6480464 sulforaphane results in increased expression of KAT2B mRNA CTD PMID:26833863 superoxide decreases abundance ISO RGD:1314209 6480464 KAT2B protein results in decreased abundance of Superoxides CTD PMID:25440059 temozolomide decreases expression ISO RGD:1314209 6480464 Temozolomide results in decreased expression of KAT2B mRNA CTD PMID:31758290 thimerosal increases expression ISO RGD:1314209 6480464 Thimerosal results in increased expression of KAT2B mRNA CTD PMID:27188386 thioacetamide decreases expression EXP 6480464 Thioacetamide results in decreased expression of KAT2B mRNA CTD PMID:34492290 triadimefon decreases expression ISO RGD:1314210 6480464 triadimefon results in decreased expression of KAT2B mRNA CTD PMID:19363144 trichostatin A affects localization ISO RGD:1314209 6480464 trichostatin A affects the localization of KAT2B protein CTD PMID:15647279 trichostatin A decreases expression ISO RGD:1314209 6480464 trichostatin A results in decreased expression of KAT2B mRNA CTD PMID:22723015 more ... trichostatin A increases expression ISO RGD:1314209 6480464 trichostatin A results in increased expression of KAT2B mRNA CTD PMID:24935251 trichostatin A multiple interactions ISO RGD:1314209 6480464 [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... CTD PMID:15647279 , PMID:27188386 triptonide increases expression ISO RGD:1314210 6480464 triptonide results in increased expression of KAT2B mRNA CTD PMID:33045310 tris(2-butoxyethyl) phosphate affects expression ISO RGD:1314209 6480464 tris(2-butoxyethyl) phosphate affects the expression of KAT2B mRNA CTD PMID:29024780 tunicamycin increases expression ISO RGD:1314210 6480464 Tunicamycin results in increased expression of KAT2B mRNA CTD PMID:17127020 tunicamycin decreases expression ISO RGD:1314209 6480464 Tunicamycin results in decreased expression of KAT2B mRNA CTD PMID:29453283 urethane increases expression ISO RGD:1314209 6480464 Urethane results in increased expression of KAT2B mRNA CTD PMID:28818685 valproic acid decreases methylation ISO RGD:1314209 6480464 Valproic Acid results in decreased methylation of KAT2B gene CTD PMID:29154799 valproic acid multiple interactions ISO RGD:1314209 6480464 [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KAT2B mRNA CTD PMID:27188386 valproic acid decreases expression ISO RGD:1314209 6480464 Valproic Acid results in decreased expression of KAT2B mRNA CTD PMID:23179753 more ... vincristine increases expression ISO RGD:1314209 6480464 Vincristine results in increased expression of KAT2B mRNA CTD PMID:16001973 zearalenone increases expression ISO RGD:1314209 6480464 Zearalenone results in increased expression of KAT2B mRNA CTD PMID:32119988 zoledronic acid multiple interactions ISO RGD:1314209 6480464 [zoledronic acid co-treated with fluvastatin] results in increased expression of KAT2B mRNA CTD PMID:16996129